Anti-PD-1 Therapy in Metastatic Melanoma

Source: OncLive, February 2019


Axel Hauschild, MD: When we discuss stage IV melanoma now, I think it’s good to provide a quick overview on ASCO [American Society of Clinical Oncology] 2018. Most of the trials that have been released as an update at ASCO with long-term survival data were done on PD-1 [programmed cell death protein 1] antibodies. Can you summarize KEYNOTE-001 and KEYNOTE-006, Caroline, and the latest findings from ASCO in terms of long-term survival? For the first time, we have seen 5-year survival data not only on nivolumab, which was presented 2 years before with a 34% 5-year survival and was exciting. Now we have the data on pembrolizumab from KEYNOTE-001 and KEYNOTE-006.

Caroline Robert, MD, PhD: KEYNOTE-001 is a huge phase I trial with 655 patients. It’s quite a heterogeneous population because we had patients who were pretreated and about 100 patients were naive. The results are a little bit better for the naive patients, but, still, we have this…

I’m not totally 100% sure that we have the plateau that we have with ipilimumab, honestly. I think we still all hope to see this very flat plateau, even though we should begin to see it with anti–PD-1 single-agent therapy. If it’s like ipilimumab, and it begins at 3 years, we should have some flattening of the curve.

read the original full article

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder